

# Agnese Latorre

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7232532/publications.pdf>

Version: 2024-02-01

31  
papers

863  
citations

567144

15  
h-index

477173

29  
g-index

31  
all docs

31  
docs citations

31  
times ranked

1347  
citing authors

| #  | ARTICLE                                                                                                                                                                                                                                                                       | IF  | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 1  | Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. <i>European Journal of Cancer</i> , 2001, 37, 364-368.                                                                                                                                     | 1.3 | 151       |
| 2  | Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of $\beta$ -tubulins. <i>International Journal of Cancer</i> , 2007, 120, 2078-2085.                                                                                                                       | 2.3 | 132       |
| 3  | Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. <i>Annals of Oncology</i> , 2005, 16, iv14-iv19.                                                                                                                           | 0.6 | 127       |
| 4  | Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 474-485.                                               | 5.1 | 59        |
| 5  | Predicting of Sentinel Lymph Node Status in Breast Cancer Patients with Clinically Negative Nodes: A Validation Study. <i>Cancers</i> , 2021, 13, 352.                                                                                                                        | 1.7 | 33        |
| 6  | Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale). <i>Annals of Oncology</i> , 2006, 17, vii15-vii17.                                      | 0.6 | 31        |
| 7  | Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum.. <i>Journal of Clinical Oncology</i> , 1997, 15, 3208-3213.                                                                                               | 0.8 | 30        |
| 8  | A multicenter REtrospective observational study of first-line treatment with PERTuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. <i>RePer Study. Cancer Biology and Therapy</i> , 2019, 20, 192-200.                                       | 1.5 | 30        |
| 9  | Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma. <i>European Journal of Cancer</i> , 1996, 32, 730-733.                                                                                                        | 1.3 | 25        |
| 10 | Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study. <i>Annals of Oncology</i> , 2007, 18, vi66-vi69.                                                                                   | 0.6 | 24        |
| 11 | A Roadmap towards Breast Cancer Therapies Supported by Explainable Artificial Intelligence. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 4881.                                                                                                                           | 1.3 | 24        |
| 12 | A Clinical Decision Support System for Predicting Invasive Breast Cancer Recurrence: Preliminary Results. <i>Frontiers in Oncology</i> , 2021, 11, 576007.                                                                                                                    | 1.3 | 21        |
| 13 | A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011, 30, 39. | 3.5 | 20        |
| 14 | A Phase I Study of Capecitabine in Combination with Vinorelbine in Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2003, 4, 138-141.                                                                                                                                  | 1.1 | 19        |
| 15 | Long-term Subcutaneous Recombinant Interleukin-2 as Maintenance Therapy: Biological Effects and Clinical Implications. <i>Cancer Biotherapy</i> , 1995, 10, 195-203.                                                                                                          | 0.6 | 18        |
| 16 | Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group) Tj ETQq0 0 0 rBT /Overlock 10 Tf 5                                           |     |           |
| 17 | Robustness Evaluation of a Deep Learning Model on Sagittal and Axial Breast DCE-MRIs to Predict Pathological Complete Response to Neoadjuvant Chemotherapy. <i>Journal of Personalized Medicine</i> , 2022, 12, 953.                                                          | 1.1 | 15        |
| 18 | Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 669-678.                           | 1.2 | 14        |

| #  | ARTICLE                                                                                                                                                                                                                                                                                                            | IF  | CITATIONS |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | FISH testing of HER2 immunohistochemistry 1+ invasive breast cancer with unfavorable characteristics. <i>Oncology Letters</i> , 2016, 12, 3115-3122.                                                                                                                                                               | 0.8 | 13        |
| 20 | Efficacy and safety of eribulin in taxane-refractory patients in the "real world". <i>Future Oncology</i> , 2017, 13, 971-978.                                                                                                                                                                                     | 1.1 | 13        |
| 21 | Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer. <i>Journal of Oncology</i> , 2020, 2020, 1-17.                                                                                                                                                                                | 0.6 | 11        |
| 22 | Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 587-594. | 1.1 | 9         |
| 23 | Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer. <i>British Journal of Cancer</i> , 2003, 88, 491-495.                                                                                                                                                       | 2.9 | 8         |
| 24 | A Multicenter Phase II Randomized Trial of Docetaxel/Gemcitabine versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Gruppo Oncologico Italia Meridionale Study. <i>Oncology</i> , 2011, 81, 230-236.                                                                              | 0.9 | 8         |
| 25 | An Invasive Disease Event-Free Survival Analysis to Investigate Ki67 Role with Respect to Breast Cancer Patients' Age: A Retrospective Cohort Study. <i>Cancers</i> , 2022, 14, 2215.                                                                                                                              | 1.7 | 4         |
| 26 | A broad Italian experience with eribulin mesylate in metastatic breast cancer patients: The ESEMPIO study. <i>Journal of Clinical Oncology</i> , 2015, 33, e11539-e11539.                                                                                                                                          | 0.8 | 3         |
| 27 | Downstream Signaling of Inflammasome Pathway Affects Patients' Outcome in the Context of Distinct Molecular Breast Cancer Subtypes. <i>Pharmaceuticals</i> , 2022, 15, 651.                                                                                                                                        | 1.7 | 3         |
| 28 | Amifostine as chemoprotectant in metastatic breast cancer patients treated with doxorubicin. <i>Oncology Reports</i> , 2003, 10, 163.                                                                                                                                                                              | 1.2 | 2         |
| 29 | Efficacy and safety of lenvatinib in an elderly patient with metastatic papillary thyroid carcinoma and cardiological comorbidity: a case report. <i>Future Oncology</i> , 2019, 15, 27-33.                                                                                                                        | 1.1 | 1         |
| 30 | Mitoxantrone, L-Leucovorin and 5-Fluorouracil: An Effective and Well Tolerated First-Line Treatment for Advanced Breast Cancer. <i>Tumori</i> , 1999, 85, 60-64.                                                                                                                                                   | 0.6 | 0         |
| 31 | Rapid tumor shrinkage with lapatinib plus capecitabine in a patient with massive liver involvement. <i>Tumori</i> , 2013, 99, 278e-81e.                                                                                                                                                                            | 0.6 | 0         |